Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount

Menarini Remains In Front

The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.

Sanofi
The failure is a blow to Sanofi's hopes of expanding its presence in oncology. • Source: Shutterstock

Sanofi is to abandon its breast cancer candidate amcenestrant, a contender in the oral selective estrogen receptor degrader (SERD) field, after a second late-stage study failure.

The decision follows an interim analysis of the Phase III AMEERA-5 trial of the drug used in tandem with Pfizer’s Ibrance (palbociclib) as a first-line treatment for patients with estrogen receptor-positive

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip